Do New Hospital Price Transparency Regulations Reflect Value in Arthroplasty?
Authors:
- Taylor D'AMoreTDTaylor D'AMore
- Graham S. GohGGGraham S. Goh
- P. Maxwell CourtneyPCP. Maxwell Courtney
- Gregg R. KleinGKGregg R. Klein
- 26 January 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Academy of Orthopaedic Surgeons
- Vol. 30 (8) , e658-e663
Abstract
Introduction: In an attempt to improve price transparency, the Centers for Medicare & Medicaid Services (CMS) now requires hospitals to post clear, accessible pricing data for common procedures. We aimed to determine how many top orthopaedic hospitals are compliant with the new regulation and whether there was any correlation between hospital charges and outcomes after total hip arthroplasty (THA) and total knee arthroplasty (TKA). Methods: The hospital websites of the top 101 orthopaedic hospitals per the US News & World Report 2020-2021 were explored to assess compliance with the price transparency requirement. We recorded the gross inpatient charge, cash price, payer-specific negotiated charge, and deidentified maximum and minimum payer rates for THA and TKA. Outcome metrics included hospital ranking and Medicare risk-adjusted arthroplasty readmission and complication rates. Results: Although 94 hospitals (93%) posted some shoppable service information as required by CMS, only 21 hospitals (20%) were fully compliant. The mean inpatient charge for THA and TKA was $72,111 (range, $14,716 to $195,264), cash price was $39,027 (range, $2,920 to $110,858), and minimum and maximum payer rates were $16,140 and $57,949, respectively. Better hospital ranking was weakly correlated with higher charges (coefficient 0.223; P = 0.049). No correlation between charges and complications (P = 0.266) or readmissions (P = 0.735) was observed. Conclusion: Few hospitals are fully compliant with the new CMS price transparency regulations. We found a wide range of hospital charges for THA and TKA without correlation with complications or readmissions. Although efforts by CMS to increase price transparency should be welcomed, increased costs should be justified by quality in the era of value-based care.Keywords
This publication has 12 references indexed in Scilit:
- Do Patient Point of Entry and Medicaid Status Affect Quality Outcomes Following Total Knee Arthroplasty?The Journal of Arthroplasty, 2020
- Price Transparency: Empowering Patient Choice and Promoting Provider CompetitionJournal of Medical Systems, 2020
- Analysis of Price Transparency via National Cancer Institute–Designated Cancer Centers’ Chargemasters for Prostate Cancer Radiation TherapyJAMA Oncology, 2020
- Costs and Outcomes of Medicare Advantage and Traditional Medicare Beneficiaries After Total Hip and Knee ArthroplastyJournal of the American Academy of Orthopaedic Surgeons, 2019
- Offering A Price Transparency Tool Did Not Reduce Overall Spending Among California Public Employees And RetireesHealth Affairs, 2017
- Market Share Matters: Evidence Of Insurer And Provider Bargaining Over PricesHealth Affairs, 2017
- Trend Toward High-Volume Hospitals and the Influence on Complications in Knee and Hip ArthroplastyJournal of Bone and Joint Surgery, 2016
- Examining A Health Care Price Transparency Tool: Who Uses It, And How They Shop For CareHealth Affairs, 2016
- Increasing the Value of Healthcare: Improving Mortality While Reducing Cost in Bariatric SurgeryObesity Surgery, 2015
- Clinical Characteristics and Outcomes of Medicare Patients Undergoing Total Hip Arthroplasty, 1991-2008JAMA, 2011